Skip to main content

Table 1 Patient demographics at baseline

From: Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial

 

n

%

83

–

Age, median and range

49 (22–78)

Tumor size, median (mm) and range

30 (20–80)

Clinical nodal status

 N0

40

48.2

 N1

30

36.1

 N2

8

9.6

 N3

1

1.2

 Nx

4

4.9

Hormone receptor status

 Negative

26

31.3

 Positive

57

68.7

Menopausal status

 Pre-menopausal

54

65.1

 Post-menopausal

29

34.9

Tumor stage

 II

65

78.3

 III

18

21.7

Histologic grade

 1

5

6.0

 2

28

33.7

 3

32

38.6

 Unknown

18

21.7